Home Plasma levels of endothelin-1 and renal function among young and healthy adults
Article
Licensed
Unlicensed Requires Authentication

Plasma levels of endothelin-1 and renal function among young and healthy adults

  • Andreas Fischer , Matthias Bossard , Stefanie Aeschbacher , Peter Egli , Carolin Cordewener , Joel Estis , John Todd , Martin Risch , Lorenz Risch and David Conen EMAIL logo
Published/Copyright: February 21, 2017
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 55 Issue 8

Abstract

Background:

Endothelin-1 (ET-1), a vasoconstrictive and pro-inflammatory peptide, is associated with several cardiovascular risk factors and outcomes. We aimed to investigate the association of plasma ET-1 levels and renal function among young and healthy adults.

Methods:

Individuals aged 25–41 years were enrolled in a population-based cohort study. Main exclusion criteria were established kidney disease, cardiovascular diseases, diabetes mellitus and a body mass index>35 kg/m2. Fasting venous plasma samples were used to measure creatinine, cystatin C and ET-1. The estimated glomerular filtration rate (eGFR) was calculated using the creatinine based chronic kidney disease epidemiology collaboration (CKD-EPI) formula. Multivariable regression models were constructed to assess interrelationships of plasma ET-1 with parameters of renal function.

Results:

Median age of the 2139 participants was 37 years, 47% males. Median creatinine and eGFR were 67 μmol/L and 112 mL/min/1.73 m2, respectively. Using quartile one as the reference group, the β-coefficients (95% confidence intervals [CIs]) for eGFR were 0.06 (− 1.22 to 1.35),−0.66 (− 1.95 to 0.62) and−1.70 (− 3.01 to−0.39) for quartiles 2–4 (p-for-trend=0.0056), respectively and β-coefficients (95% CIs) for cystatin C were 0.002 (− 0.01 to 0.02), 0.02 (0.003–0.03) and 0.03 (0.01–0.04) for quartiles 2–4 (p-for-trend<0.0001), respectively. Using ET-1 as a continuous variable, the β-coefficient (95% CI) for eGFR per 1-unit increase was−1.82 (− 3.19 to−0.44, p=0.0095) and 0.02 (0.01–0.04, p=0.0003) for cystatin C. Similar results were found between creatinine and ET-1 levels.

Conclusions:

ET-1 levels are strongly associated with parameters of renal function among young and healthy adults, suggesting an important role of ET-1 and endothelial function in the regulation of kidney function.

Keywords: chronic kidney disease; endothelin-1; epidemiology; glomerular filtration rate; population based; renal function
Corresponding author: Assoc. Prof. Dr. David Conen, MD, MPH, Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, McMaster University, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada, Phone: + 1 905 905 522 (Ext. 1155)
aAndreas Fischer and Matthias Bossard contributed equally to this work and are shared first authors.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: The Swiss National Science Foundation, the Liechtenstein Government, the Swiss Heart Foundation, the Swiss Society of Hypertension, the University of Basel, the University Hospital Basel, the Hanela Foundation, Schiller AG and Novartis Foundation supported the GAPP study. Endothelin-1 was measured free of charge by Singulex, Inc., Alameda, CA 94502, USA. Samples were provided and tested for endothelin-1 at Singulex in a blinded manner without access to any variables in the study database other than patient identifiers. Matthias Bossard was supported by grants of the University of Basel and Freiwillige Akademische Gesellschaft (FAG) Basel.

  3. Employment or leadership: John Todd and Joel Estis are employees of Singulex, Inc.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007;298:2038–47.10.1001/jama.298.17.2038Search in Google Scholar

2. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010;375:1296–309.10.1016/S0140-6736(09)62004-3Search in Google Scholar

3. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158–69.10.1016/S0140-6736(13)60439-0Search in Google Scholar

4. Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health 2016;4:e307–19.10.1016/S2214-109X(16)00071-1Search in Google Scholar

5. Astor BC, Hallan SI, Miller ER, 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008;167:1226–34.10.1093/aje/kwn033Search in Google Scholar

6. Chugh S, Chugh Y. Radial artery occlusion: size and more–how small is too small? J Invasive Cardiol 2015;27:E113.Search in Google Scholar

7. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213–24.10.1681/ASN.2007090970Search in Google Scholar

8. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–5.10.1038/332411a0Search in Google Scholar

9. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997–1001.10.1056/NEJM199110033251404Search in Google Scholar

10. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852–4.10.1016/S0140-6736(94)92827-4Search in Google Scholar

11. Speed JS, Pollock DM. Endothelin, kidney disease, and hypertension. Hypertension 2013;61:1142–5.10.1161/HYPERTENSIONAHA.113.00595Search in Google Scholar PubMed PubMed Central

12. Lerman A, Holmes DR Jr., Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426–31.10.1161/01.CIR.92.9.2426Search in Google Scholar PubMed

13. Barton M, Haudenschild CC, d’Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998;95:14367–72.10.1073/pnas.95.24.14367Search in Google Scholar PubMed PubMed Central

14. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890–6.10.1161/01.CIR.0000015126.83143.B4Search in Google Scholar PubMed

15. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004;110:2233–40.10.1161/01.CIR.0000144462.08345.B9Search in Google Scholar PubMed

16. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010;122:958–66.10.1161/CIRCULATIONAHA.110.967406Search in Google Scholar PubMed PubMed Central

17. Li MW, Mian MO, Barhoumi T, Rehman A, Mann K, Paradis P, et al. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2013;33:2306–15.10.1161/ATVBAHA.113.302028Search in Google Scholar PubMed

18. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354–8.10.1038/ki.1993.53Search in Google Scholar PubMed

19. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380–9.10.1172/JCI119297Search in Google Scholar PubMed PubMed Central

20. Fligny C, Barton M, Tharaux PL. Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol 2011;172:120–38.10.1159/000328692Search in Google Scholar PubMed

21. Lenoir O, Milon M, Virsolvy A, Henique C, Schmitt A, Masse JM, et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol 2014;25:1050–62.10.1681/ASN.2013020195Search in Google Scholar PubMed PubMed Central

22. Barton M, Sorokin A. Endothelin and the glomerulus in chronic kidney disease. Semin Nephrol 2015;35:156–67.10.1016/j.semnephrol.2015.02.005Search in Google Scholar PubMed PubMed Central

23. Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 2007;53:1990–5.10.1373/clinchem.2007.091181Search in Google Scholar PubMed

24. Bossard M, Pumpol K, van der Lely S, Aeschbacher S, Schoen T, Krisai P, et al. Plasma endothelin-1 and cardiovascular risk among young and healthy adults. Atherosclerosis 2015;239:186–91.10.1016/j.atherosclerosis.2014.12.061Search in Google Scholar PubMed

25. Conen D, Schon T, Aeschbacher S, Pare G, Frehner W, Risch M, et al. Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP). Swiss Med Wkly 2013;143:w13728.10.4414/smw.2013.13728Search in Google Scholar PubMed

26. Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987;10:414–8.10.2337/diacare.10.4.414Search in Google Scholar PubMed

27. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3:1–150.Search in Google Scholar

28. Kawasaki T, Itoh K, Uezono K, Sasaki H. A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol 1993;20:7–14.10.1111/j.1440-1681.1993.tb01496.xSearch in Google Scholar PubMed

29. Standards of medical care in diabetes–2012. Diabetes Care 2012;35(Suppl 1):S11–63.10.2337/dc12-s011Search in Google Scholar PubMed PubMed Central

30. Cody RJ, Ljungman S, Covit AB, Kubo SH, Sealey JE, Pondolfino K, et al. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int 1988;34:361–7.10.1038/ki.1988.189Search in Google Scholar PubMed

31. Kohan DE, Inscho EW, Wesson D, Pollock DM. Physiology of endothelin and the kidney. Compr Physiol 2011;1:883–919.10.1002/cphy.c100039Search in Google Scholar PubMed PubMed Central

32. Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014;86:896–904.10.1038/ki.2014.143Search in Google Scholar PubMed PubMed Central

33. Zeravica R, Cabarkapa V, Ilincic B, Sakac V, Mijovic R, Nikolic S, et al. Plasma endothelin-1 level, measured glomerular filtration rate and effective renal plasma flow in diabetic nephropathy. Ren Fail 2015;37:681–6.10.3109/0886022X.2015.1010990Search in Google Scholar PubMed

34. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation 1997;96:3053–62.10.1161/01.CIR.96.9.3053Search in Google Scholar

35. Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010;19:134–9.10.1097/MNH.0b013e328335f91fSearch in Google Scholar PubMed PubMed Central

36. Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacques-Silva MC, Canani LH, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;80:299–304.10.1016/j.diabres.2007.12.024Search in Google Scholar PubMed

37. Seliger SL, Salimi S, Pierre V, Giffuni J, Katzel L, Parsa A. Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults. BMC Nephrol 2016;17:82.10.1186/s12882-016-0303-xSearch in Google Scholar PubMed PubMed Central

38. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.10.7326/0003-4819-150-9-200905050-00006Search in Google Scholar PubMed PubMed Central

39. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010;56:486–95.10.1053/j.ajkd.2010.03.026Search in Google Scholar PubMed PubMed Central

40. Florkowski CM, Chew-Harris JS. Methods of estimating GFR – different equations including CKD-EPI. Clin Biochem Rev 2011;32:75–9.Search in Google Scholar

41. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 2001;104:864–9.10.1161/hc3301.094742Search in Google Scholar PubMed

Received: 2016-10-12
Accepted: 2017-1-10
Published Online: 2017-2-21
Published in Print: 2017-7-26

©2017 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Biomarkers of acute kidney injury: a step forward
  4. Reviews
  5. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption
  6. Prognostic value of glycated hemoglobin among patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis
  7. Opinion Paper
  8. Traceability in laboratory medicine: a global driver for accurate results for patient care
  9. Point
  10. To report or not to report: a proposal on how to deal with altered test results in hemolytic samples
  11. Counterpoint
  12. Reporting altered test results in hemolyzed samples: is the cure worse than the disease?
  13. Genetics and Molecular Diagnostics
  14. Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation
  15. Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping
  16. General Clinical Chemistry and Laboratory Medicine
  17. The relationship between vacuum and hemolysis during catheter blood collection: a retrospective analysis of six large cohorts
  18. Evaluation of the Greiner Bio-One serum separator BCA Fast Clot tube
  19. Implementation and application of moving average as continuous analytical quality control instrument demonstrated for 24 routine chemistry assays
  20. Parathormone stability in hemodialyzed patients and healthy subjects: comparison on non-centrifuged EDTA and serum samples with second- and third-generation assays
  21. Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study
  22. Activity of the liver enzyme ornithine carbamoyltransferase (OTC) in blood: LC-MS/MS assay for non-invasive diagnosis of ornithine carbamoyltransferase deficiency
  23. Detecting paraprotein interference on a direct bilirubin assay by reviewing the photometric reaction data
  24. Prediction of human iron bioavailability using rapid c-ELISAs for human plasma hepcidin
  25. Reference Values and Biological Variations
  26. Determination of glucose-6-phosphate dehydrogenase cut-off values in a Tunisian population
  27. Plasma levels of endothelin-1 and renal function among young and healthy adults
  28. Cancer Diagnostics
  29. A new strategy for calculating the risk of ovarian malignancy algorithm (ROMA)
  30. Laboratory characterization of leukemic cell procoagulants
  31. Diabetes
  32. Preparation, calibration and evaluation of the First International Standard for human C-peptide
  33. Hb variants in Korea: effect on HbA1c using five routine methods
  34. Letters to the Editor
  35. Pseudohyperkalemia in capillary whole-blood samples – an occasional error or a significant problem in a pediatric hospital?
  36. Elevation of creatine kinase is linked to disease severity and predicts fatal outcomes in H7N9 infection
  37. Analytical evaluation of point-of-care procalcitonin (PCT) and clinical performances in an unselected population as compared with central lab PCT assay
  38. Evaluation of an automated commercial ELISA method for calprotectin determination in pleural fluid
  39. The unfinished story of interference in thyroid hormones with Roche immunoassays: when prewashing procedures matter
  40. Effects of apixaban on prothrombin time, activated partial thromboplastin time and anti-Xa assays: a European survey
  41. Evaluation of a chemiluminescent immunoassay for urinary aldosterone on the DiaSorin LIAISON automated platform against RIA and LC-MS/MS
  42. Complex considerations when tendering for HbA1c analysers
https://doi.org/10.1515/cclm-2016-0920
Keywords for this article
chronic kidney disease; endothelin-1; epidemiology; glomerular filtration rate; population based; renal function

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Biomarkers of acute kidney injury: a step forward
  4. Reviews
  5. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption
  6. Prognostic value of glycated hemoglobin among patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis
  7. Opinion Paper
  8. Traceability in laboratory medicine: a global driver for accurate results for patient care
  9. Point
  10. To report or not to report: a proposal on how to deal with altered test results in hemolytic samples
  11. Counterpoint
  12. Reporting altered test results in hemolyzed samples: is the cure worse than the disease?
  13. Genetics and Molecular Diagnostics
  14. Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation
  15. Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping
  16. General Clinical Chemistry and Laboratory Medicine
  17. The relationship between vacuum and hemolysis during catheter blood collection: a retrospective analysis of six large cohorts
  18. Evaluation of the Greiner Bio-One serum separator BCA Fast Clot tube
  19. Implementation and application of moving average as continuous analytical quality control instrument demonstrated for 24 routine chemistry assays
  20. Parathormone stability in hemodialyzed patients and healthy subjects: comparison on non-centrifuged EDTA and serum samples with second- and third-generation assays
  21. Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study
  22. Activity of the liver enzyme ornithine carbamoyltransferase (OTC) in blood: LC-MS/MS assay for non-invasive diagnosis of ornithine carbamoyltransferase deficiency
  23. Detecting paraprotein interference on a direct bilirubin assay by reviewing the photometric reaction data
  24. Prediction of human iron bioavailability using rapid c-ELISAs for human plasma hepcidin
  25. Reference Values and Biological Variations
  26. Determination of glucose-6-phosphate dehydrogenase cut-off values in a Tunisian population
  27. Plasma levels of endothelin-1 and renal function among young and healthy adults
  28. Cancer Diagnostics
  29. A new strategy for calculating the risk of ovarian malignancy algorithm (ROMA)
  30. Laboratory characterization of leukemic cell procoagulants
  31. Diabetes
  32. Preparation, calibration and evaluation of the First International Standard for human C-peptide
  33. Hb variants in Korea: effect on HbA1c using five routine methods
  34. Letters to the Editor
  35. Pseudohyperkalemia in capillary whole-blood samples – an occasional error or a significant problem in a pediatric hospital?
  36. Elevation of creatine kinase is linked to disease severity and predicts fatal outcomes in H7N9 infection
  37. Analytical evaluation of point-of-care procalcitonin (PCT) and clinical performances in an unselected population as compared with central lab PCT assay
  38. Evaluation of an automated commercial ELISA method for calprotectin determination in pleural fluid
  39. The unfinished story of interference in thyroid hormones with Roche immunoassays: when prewashing procedures matter
  40. Effects of apixaban on prothrombin time, activated partial thromboplastin time and anti-Xa assays: a European survey
  41. Evaluation of a chemiluminescent immunoassay for urinary aldosterone on the DiaSorin LIAISON automated platform against RIA and LC-MS/MS
  42. Complex considerations when tendering for HbA1c analysers
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 28.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-0920/html
Scroll to top button